Ticker: ACN

Accenture

Software Technology Information Technology Services
Price 146.99
Reco Sell Potential 52 Risk 75 Updated 2026-07-27

Forecast impact

negative
Target +32.0% target fill 75.8%
Reaction D5 pending · D10 pending market trust
Impact Potential -4 · Risk +3 valid until 2026-08-19

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell
Description

Company and Business Model

Accenture is a global professional services company specializing in consulting, technology services, and outsourcing. Its core offerings include digital transformation, technology implementation, and management consulting across various industries. Major business segments encompass strategy and consulting, digital services, technology, and operations. The company generates revenue primarily from client contracts in these segments, focusing on delivering innovative solutions to enhance business performance.

Investment Profile

Accenture's stock presents a balanced investment profile, appealing to investors seeking a mix of growth and income through dividends. The company offers a moderate dividend yield, while its focus on technology and consulting positions it for potential growth. However, recent revenue decline may indicate caution for growth-oriented investors. The stock is suitable for those with a medium to long-term investment horizon, providing reasonable liquidity for various investor experiences.

Fundamental metrics (experimental) Updated: 2026-07-24
EPS (TTM) — earnings per share for the last 12 months, $
12.62
Revenue QoQ — quarter-over-quarter revenue growth
3.7%
EPS surprise
2.7%
20d volatility
2.6%
Dividend yield
4.7%
last ex-date
2026-07-09
AI recommendation changes
Date Before After Reason
2026-07-27 Hold Sell Mixed performance; high risk and negative momentum persist.
2026-07-20 Sell Hold Mixed performance; cautious outlook amid high risk.
2026-06-09 Hold Sell Weak fundamentals and negative momentum indicate high risk.
Analyst forecasts
Date Analyst Action Target Price Then
2026-07-20 Wells Fargo Target Lowered 200 → 194 143.57
2026-07-10 Deutsche Bank Target Lowered 140 → 136 139.06
2026-07-08 UBS Update — → 275 139.72
News Page 1 of 1
Accenture Intercontinental Exchange Medtronic Abbott Laboratories

Analysts recommend buying dividend stocks like Abbott Laboratories (ABT) and Accenture (ACN) for portfolio income in 2026

In a high-priced stock market, investors are increasingly looking for undervalued dividend stocks that provide income while they wait for potential price appreciation. This strategy is particularly relevant given the current market volatility and inflation concerns.
SpaceX Marvell Technology Accenture Intel Apple Pfizer Lam Research

Stocks Making Significant Moves in Premarket Trading: Intel, SpaceX, Micron, Carnival, and More

Intel's stock surged nearly 9% following news of a deal with Apple to design and manufacture chips in the U.S., positively impacting the semiconductor sector and related stocks. Meanwhile, Pfizer's shares dipped after the CFO announced his departure, and Accenture's stock fell 13% due to a significant acquisition.
Accenture Broadcom

Analysts UBS recommend buying Broadcom (AVGO) and Accenture (ACN) shares despite market highs

UBS identifies potential investment opportunities in the current high stock market, highlighting Broadcom and Accenture as key picks based on their improving fundamentals and market positioning. This analysis suggests that even at record highs, savvy investors can find value in specific sectors.